Organization (Industry)
PIERRE FABRE SA
ClinicalTrials.gov lists PIERRE FABRE SA as lead sponsor of 140 trials, counting the companies grouped under it. PIERRE FABRE SA itself has 9 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers PIERRE FABRE SA and 4 companies grouped under it: 140 lead-sponsored trials (8 its own, 132 in the grouped companies) and 11 legal-entity registrations (5 its own, 6 in the grouped companies).
Companies grouped under this page (4)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| PIERRE FABRE MEDICAMENT | 73 | 1 |
| PIERRE FABRE DERMO-COSMETIQUE | 59 | 1 |
| INSTITUT DE RECHERCHE PIERRE FABRE | 0 | 3 |
| PIERRE FABRE MEDICAMENT PRODUCTION | 0 | 1 |
Disease areas (10)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 4 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Colorectal Neoplasms | 3 |
| Lung Neoplasms | 3 |
| Melanoma | 3 |
Showing 5 of 10 disease areas.
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 2 |
| 2022 | 1 |
| 2020 | 3 |
| 2019 | 1 |
| 2016 | 2 |
| 2010 | 1 |
| 2009 | 1 |
| 2005 | 1 |
| 2002 | 1 |
Recruitment duration, a model prediction: none of the 8 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (9)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Encorafenib + Binimetinib | Melanoma | Not reported | 1 |
| Binimetinib | Melanoma | Not reported | 1 |
| Encorafenib | Melanoma | Not reported | 1 |
| Encorafenib | Colorectal Neoplasms | Not reported | 1 |
| CETUXIMAB | Colorectal Neoplasms | Not reported | 1 |
Showing 5 of 9 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Encorafenib | 2 |
| Binimetinib | 1 |
| NERATINIB | 1 |
| CETUXIMAB | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 2 hit target (n=2) | 2 of 3 on time (n=3) |
Journals published in (2)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Archives of gynecology and obstetrics | 1 |
| Journal of cancer research and clinical oncology | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 48 | 0 | 1991-07-09 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 4 | 2025-11-14 |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Winicker Norimed GmbH (Germany) | Co sponsors trial with | 1 |
| Vitaccess Ltd | Co sponsors trial with | 1 |
| Pierre Fabre Pharma Austria | Co sponsors trial with | 1 |
| Fondazione Italiana Linfomi - ETS | Co sponsors trial with | 1 |
| Charite University, Berlin, Germany | Co sponsors trial with | 1 |
Latest dated events (67)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-14 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-07-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-01-21 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2024-10-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 67 events.
Biomarker capability evidence (58)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial collaborator | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial collaborator | Named in trial inclusion criteria |
| BRAF | Trial sponsor | Named in trial inclusion criteria |
| BRAF | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 58 evidence rows.
On Scientist.com
PIERRE FABRE SA is listed as a research supplier in the Scientist.com network.
Service areas
Pierre Fabre offers products based on therapeutic areas, dermo-cosmetics and family medication.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Pierre Fabre on Scientist.com
For prices, more details, or to contact Pierre Fabre, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.